ATE367802T1 - METHOD FOR SPRAY DRYING COMPOSITIONS CONTAINING FENOFIBRATE - Google Patents

METHOD FOR SPRAY DRYING COMPOSITIONS CONTAINING FENOFIBRATE

Info

Publication number
ATE367802T1
ATE367802T1 AT01937182T AT01937182T ATE367802T1 AT E367802 T1 ATE367802 T1 AT E367802T1 AT 01937182 T AT01937182 T AT 01937182T AT 01937182 T AT01937182 T AT 01937182T AT E367802 T1 ATE367802 T1 AT E367802T1
Authority
AT
Austria
Prior art keywords
fenofibrate
spray drying
compositions containing
powdered compositions
dosage forms
Prior art date
Application number
AT01937182T
Other languages
German (de)
Inventor
Gary Pace
Awadhesh Mishra
Robert Snow
Indu Parikh
H Pol-Henri Dr Guivarc
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Application granted granted Critical
Publication of ATE367802T1 publication Critical patent/ATE367802T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel spray drying process for the preparation of pharmaceutical compositions containing small particles of phospholipid-stabilized fenofibrate. This invention also relates to spray dried powdered compositions prepared according to this process, and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compositions. The powdered compositions and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally.
AT01937182T 2000-09-20 2001-04-20 METHOD FOR SPRAY DRYING COMPOSITIONS CONTAINING FENOFIBRATE ATE367802T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23418600P 2000-09-20 2000-09-20
US24176100P 2000-10-20 2000-10-20
US27015701P 2001-02-22 2001-02-22

Publications (1)

Publication Number Publication Date
ATE367802T1 true ATE367802T1 (en) 2007-08-15

Family

ID=27398528

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01937182T ATE367802T1 (en) 2000-09-20 2001-04-20 METHOD FOR SPRAY DRYING COMPOSITIONS CONTAINING FENOFIBRATE

Country Status (9)

Country Link
US (1) US6696084B2 (en)
EP (1) EP1322289B1 (en)
AT (1) ATE367802T1 (en)
AU (2) AU6294501A (en)
CA (1) CA2423335C (en)
DE (1) DE60129573T2 (en)
NZ (1) NZ525306A (en)
TW (1) TWI293877B (en)
WO (1) WO2002024169A1 (en)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US6182712B1 (en) 1997-07-21 2001-02-06 Inhale Therapeutic Systems Power filling apparatus and methods for their use
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
EP2266542A3 (en) * 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
IL143197A0 (en) * 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2795961B1 (en) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED FENOFIBRATE, A SURFACTANT AND A BINDING CELLULOSIC DERIVATIVE AND PREPARATION METHOD
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7122376B2 (en) * 2001-11-01 2006-10-17 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US7049146B2 (en) 2000-11-14 2006-05-23 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
BR0212833A (en) 2001-09-26 2004-10-13 Baxter Int Preparation of submicron sized nanoparticles by dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
EP1499296B1 (en) * 2002-04-15 2012-04-04 MAP Pharmaceuticals Inc Formulation of fine particles using liquefied or dense gases
NO346970B1 (en) * 2002-05-24 2023-03-20 Alkermes Pharma Ireland Ltd Nanoparticulate fiber formulations
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
WO2003103640A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (“statins”), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
EP1515890B1 (en) * 2002-06-27 2012-07-11 Novartis AG Device and method for controlling the flow of a powder
MXPA05007485A (en) 2003-01-14 2006-01-30 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia.
WO2004096113A2 (en) 2003-04-28 2004-11-11 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
RS20060018A (en) 2003-07-14 2007-12-31 Arena Pharmaceuticals Inc., Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
MXPA06003813A (en) * 2003-10-10 2006-06-14 Lifecycle Pharma As SOLID FORM OF DOSAGE THAT INCLUDES A FIBRATE AND A STATIN.
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
CA2540984C (en) 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
ATE428411T1 (en) * 2003-11-07 2009-05-15 Jj Pharma Inc HDL-BOOSTING COMBINATION THERAPY COMPLEXES
AU2005231355B2 (en) * 2004-03-30 2008-09-18 Smithkline Beecham Corporation Spray dried pharmaceutical compositions
EP1730516A1 (en) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Method and device for evaluation of pharmaceutical compositions
US7101585B2 (en) * 2004-04-15 2006-09-05 Solae, Llc Ultra high pressure homogenization process for making a stable protein based acid beverage
US7306562B1 (en) * 2004-04-23 2007-12-11 Medical Software, Llc Medical risk assessment method and program product
GB0411502D0 (en) * 2004-05-22 2004-06-23 Britannia Pharmaceuticals Ltd Pharmaceutical compositions
US7495052B2 (en) * 2004-09-15 2009-02-24 Bausch & Lomb Incorporated Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US20060057216A1 (en) * 2004-09-15 2006-03-16 Salamone Joseph C Low-obscuration image transmitting particulate ocular therapeutic formulations
US20060057215A1 (en) * 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
WO2006037345A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical composition comprising fenofibrate and simvastatin
CA2582403A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
JP2008521878A (en) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Pharmaceutical composition of amorphous atorvastatin and process for its production
RU2007133601A (en) * 2005-02-10 2009-03-20 Лайфсайкл Фарма А/С (Dk) SUSTAINABLE PHARMACEUTICAL COMPOSITION CONTAINING A FIXED DOSE OF A COMBINATION OF Phenofibrate and an HMG-CoA reductase inhibitor
DE102005011786A1 (en) * 2005-03-11 2006-09-14 Pharmasol Gmbh Process for preparing ultrafine submicron suspensions
US20060223882A1 (en) * 2005-03-23 2006-10-05 Venkataraman Sundaram Amorphous simvastatin
EP1861084A1 (en) * 2005-03-30 2007-12-05 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or peg/poloxamer
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
JP2008534586A (en) * 2005-03-30 2008-08-28 テバ ファーマシューティカル インダストリーズ リミティド Improved formulation of fenofibrate
WO2006084475A2 (en) * 2005-04-13 2006-08-17 Lifecycle Pharma A/S A tablet comprising a fibrate
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
RU2395280C2 (en) * 2005-11-21 2010-07-27 Тева Фармасьютикл Индастриес Лтд. Pharmaceutical medical form of atorvastatin
EP1808162A1 (en) * 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Atorvastatin pharmaceutical formulation
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
BRPI0520821A2 (en) * 2005-12-28 2009-06-30 Teva Pharma fenofibrate pharmaceutical formulations with improved bioavailability
DE602005014258D1 (en) * 2005-12-28 2009-06-10 Teva Pharma Pharmaceutical formulations with fenofibrate with improved bioavailability
EP1905424A3 (en) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
WO2007100609A2 (en) * 2006-02-24 2007-09-07 Albert Einstein College Of Medicine Of Yeshiva University Electron transfer through glassy matrices
WO2007127286A2 (en) 2006-04-24 2007-11-08 Medical Instill Technologies, Inc. Needle penetrable and laser resealable lyophilization device and related method
EP1870649A1 (en) * 2006-06-20 2007-12-26 Octapharma AG Lyophilisation targetting defined residual moisture by limited desorption energy levels
BRPI0713533A2 (en) * 2006-06-26 2012-04-17 Mutual Pharmaceutical Co active agent formulations, manufacturing methods, and methods of use
US7877895B2 (en) 2006-06-26 2011-02-01 Tokyo Electron Limited Substrate processing apparatus
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
PT2046292E (en) * 2006-07-21 2010-04-26 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
KR20090027734A (en) * 2006-07-27 2009-03-17 (주)아모레퍼시픽 Method for preparing a powder containing nanoparticles of poorly soluble drugs
US20080132560A1 (en) * 2006-11-21 2008-06-05 San-Laung Chow Solid dispersion composition
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US7908765B2 (en) * 2006-12-22 2011-03-22 Collette Nv Continuous granulating and drying apparatus
US20080161594A1 (en) * 2006-12-29 2008-07-03 Industrial Technology Research Institute Method for fabricating nanoparticles containing fenofibrate
US7872560B2 (en) * 2007-03-19 2011-01-18 Abc Taiwan Electronics Corp. Independent planar transformer
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2162120B1 (en) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
DK2200588T3 (en) 2007-09-25 2019-07-01 Solubest Ltd COMPOSITIONS CONCERNING LIPOFILE ACTIVE RELATIONS AND METHOD OF PRODUCTION THEREOF
WO2009073216A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
EP2231169B1 (en) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009085766A2 (en) * 2007-12-19 2009-07-09 Mutual Pharmaceutical Company, Inc. Fenofibric acid amorphous dispersion; method of making; and method of use thereof
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
EP2411137B1 (en) 2009-03-27 2016-09-07 Bend Research, Inc. Spray-drying process
BRPI1006722A2 (en) 2009-04-09 2017-10-10 Entegrion Inc "method of preparing dehydrated blood products, dehydrated blood products, bandage or surgical aids, method for preparing dehydrated fixed blood platelets, dehydrated fixed blood platelets, method for treating a patient suffering from a blood disorder and dry fixed blood platelets" by atomization having geometry with spherical cavities "
WO2011035062A2 (en) 2009-09-16 2011-03-24 Velico Medical, Inc. Spray dried human plasma
KR100980749B1 (en) 2009-12-17 2010-09-07 삼일제약주식회사 Fenofibrate-containing granules and pharmaceutical composition comprising the same
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
WO2012031133A2 (en) 2010-09-03 2012-03-08 Bench Research, Inc. Spray-drying apparatus and methods of using the same
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
CN104470503A (en) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 Aggregate particles
US8722083B2 (en) 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
MX2013006332A (en) * 2013-06-05 2014-12-19 Alparis Sa De Cv Oral pharmaceutical compositions for use in dyslipidemias.
EP2878311A1 (en) * 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Solubility Enhancement for Hydrophobic Drugs
DK3154528T3 (en) 2014-06-11 2023-04-24 SpecGx LLC SPRAY DRIED COMPOSITIONS WITH DIFFERENT DISSOLUTION PROFILES AND METHODS FOR THEIR PREPARATION
US9561184B2 (en) 2014-09-19 2017-02-07 Velico Medical, Inc. Methods and systems for multi-stage drying of plasma
WO2016067132A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
PL3242666T3 (en) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
BR112017027656B1 (en) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. CRYSTALLINE HABIT OF SALT-FREE PLATE OF ACID L-ARGININE (R)-2-(7-(4- CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)- 1,2,3,4-TETRA-HYDROCYCLO-PENTA[B ]INDOL-3- IL)ACETIC, PHARMACEUTICAL COMPOSITION THAT COMPRISES IT, ITS USES AND METHOD OF PREPARATION THEREOF
MX2019009841A (en) 2017-02-16 2020-01-30 Arena Pharm Inc Compounds and methods for treatment of primary biliary cholangitis.
US10627161B2 (en) * 2018-01-24 2020-04-21 King Abdulaziz City for Science and Technology (KACST) Laboratory equipment and method of using the same for drying a starting material to produce nano material
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
WO2022183281A1 (en) * 2021-03-03 2022-09-09 Mcmaster Christopher R Compounds and treatments for muscular dystrophy
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products
USD1081739S1 (en) 2021-04-06 2025-07-01 Altria Client Services Llc Die for gum forming
US12571587B2 (en) * 2022-09-15 2026-03-10 Velico Medical, Inc. Finishing apparatus for a spray drying system
US11975274B2 (en) 2022-09-15 2024-05-07 Velico Medical, Inc. Blood plasma product
US12083447B2 (en) 2022-09-15 2024-09-10 Velico Medical, Inc. Alignment of a disposable for a spray drying plasma system
US12246266B2 (en) 2022-09-15 2025-03-11 Velico Medical, Inc. Disposable for a spray drying system
US11998861B2 (en) 2022-09-15 2024-06-04 Velico Medical, Inc. Usability of a disposable for a spray drying plasma system
US12539355B2 (en) * 2022-09-15 2026-02-03 Velico Medical, Inc. Dryer for a spray drying system
WO2024059770A1 (en) 2022-09-15 2024-03-21 Velico Medical, Inc. Rapid spray drying system
US11841189B1 (en) 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system
US12246093B2 (en) 2022-09-15 2025-03-11 Velico Medical, Inc. Methods for making spray dried plasma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329446A1 (en) * 1993-09-01 1995-03-02 Basf Ag Process for the production of finely divided color or active substance preparations
FR2737121B1 (en) * 1995-07-27 1997-10-03 Cl Pharma NEW GALENIC FORMULATIONS OF FENOFIBRATE AND THEIR APPLICATIONS
DK0807431T3 (en) 1996-05-14 2004-07-26 Dsm Ip Assets Bv Process for the preparation of carotenoid preparations
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
DE19858789A1 (en) * 1998-12-18 2000-06-21 Bayer Ag Medicament combination of cerivastatin and fibrate, has additive effect in the treatment of lipid metabolism disorders, e.g. dyslipidemia or atherosclerosis

Also Published As

Publication number Publication date
DE60129573D1 (en) 2007-09-06
US6696084B2 (en) 2004-02-24
WO2002024169A1 (en) 2002-03-28
CA2423335C (en) 2011-03-01
NZ525306A (en) 2004-11-26
TWI293877B (en) 2008-03-01
DE60129573T2 (en) 2008-04-17
CA2423335A1 (en) 2002-03-28
US20020056206A1 (en) 2002-05-16
EP1322289A1 (en) 2003-07-02
EP1322289B1 (en) 2007-07-25
AU2001262945B2 (en) 2006-02-02
AU6294501A (en) 2002-04-02

Similar Documents

Publication Publication Date Title
ATE367802T1 (en) METHOD FOR SPRAY DRYING COMPOSITIONS CONTAINING FENOFIBRATE
KR100757155B1 (en) Low dose entecavir formulations and uses thereof
CA2874779C (en) Pharmaceutical composition of entecavir and process of manufacturing
EA029890B1 (en) PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION IN ORAL DOSED DOSAGE FORM BASED ON DPP IV INHIBITOR
DK1094788T3 (en) Taste masking with croscarmellose
EA017764B8 (en) Pharmaceutical composition, method for preparation thereof and method for treating antiviral diseases using same
NO20011211D0 (en) Multiple unit for controlled feed effect-independent release of pharmaceutical preparations and methods for the preparation of the same
MXPA04007427A (en) Dry granulated formulations of azithromycin.
RU2002123182A (en) CONTAINING IBUPROFEN COMPOSITION
MXPA04003346A (en) Flashmelt oral dosage formulation.
RU2199312C1 (en) Method of preparing medicinal agents in solid form from vegetable extracts
JPH0225428A (en) Reduction of bitterness and bitterness reducing composition
RU2287338C2 (en) Method for obtaining tablets out of dry st. john's wort extract
JP2011162458A (en) Oral medicinal composition having masked disagreeable taste of medicine
RU2188017C1 (en) Method for obtaining tablets of combined trimetoprime preparation and sulfametoxasole
AU2006235960B2 (en) Low dose entecavir formulation and use
EP3900708A1 (en) Extended-release medical composition containing zaltoprofen
EP1013271A2 (en) Nimodipine tablets
NZ533283A (en) High-dosage nelfinavir tablet comprising nelfinavir mesylate in an amount of up to 730 mg
RU2190403C1 (en) Pharmaceutical composition showing antibacterial effect and method of its preparing
KR20010089479A (en) Method for producing medicaments from plant extracts, in a solid form of administration
AU2003239460A1 (en) Increased-dosage nelfinavir tablet and method of making same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties